Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype

An integrated encyclopedia of DNA elements in the human genome

The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072 · see citing works

Role of YAP/TAZ in mechanotransduction

Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979 · see citing works

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · see citing works

<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622 · see citing works

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499 · see citing works

Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · see citing works

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770 · see citing works

Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer

Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · see citing works

A Landscape of Pharmacogenomic Interactions in Cancer

Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.017 · Cited by 2,090 · see citing works

Open-Label Phase III Trial of Panitumumab plus Best Supportive Care Compared with Best Supportive Care Alone in Patients with Chemotherapy-Refractory Metastatic Colorectal Cancer

Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979 · see citing works

A single-cell survey of the small intestinal epithelium

Haber, A. L., Biton, M., Rogel, N., Herbst, R. H., Shekhar, K., Smillie, C., Burgin, G., Delorey, T. M., Howitt, M. R., Katz, Y., et al. (2017) · Nature · doi:10.1038/nature24489 · Cited by 1,750 · see citing works

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346 · see citing works

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function

Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., et al. (2014) · Nature · doi:10.1038/nature13611 · Cited by 1,259 · see citing works

Expression of Epiregulin and Amphiregulin and <i>K-ras</i> Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125 · see citing works

The ERBB network: at last, cancer therapy meets systems biology

Yarden, Y., & Pines, G. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3309 · Cited by 998 · see citing works

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985 · see citing works

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967 · see citing works

A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · see citing works

Toward Minimal Residual Disease-Directed Therapy in Melanoma

Rambow, F., Rogiers, A., Marin-Bejar, O., Aibar, S., Femel, J., Dewaele, M., Karras, P., Brown, D., Chang, Y. H., Debiec-Rychter, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.025 · Cited by 771 · see citing works

Intestinal label-retaining cells are secretory precursors expressing Lgr5

Buczacki, S. J. A., Zecchini, H. I., Nicholson, A. M., Russell, R., Vermeulen, L., Kemp, R., & Winton, D. J. (2013) · Nature · doi:10.1038/nature11965 · Cited by 761 · see citing works

Paneth Cells: Maestros of the Small Intestinal Crypts

Clevers, H. C., & Bevins, C. L. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183744 · Cited by 699 · see citing works

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663 · see citing works

Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657 · see citing works

Yap-dependent reprogramming of Lgr5+ stem cells drives intestinal regeneration and cancer

Gregorieff, A., Liu, Y., Inanlou, M. R., Khomchuk, Y., & Wrana, J. L. (2015) · Nature · doi:10.1038/nature15382 · Cited by 647 · see citing works

Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

Ramirez, M., Rajaram, S., Steininger, R. J., Osipchuk, D., Roth, M. A., Morinishi, L. S., Evans, L., Ji, W., Hsu, C.-H., Thurley, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms10690 · Cited by 581 · see citing works

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551 · see citing works

The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer

Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature · doi:10.1038/nature14969 · Cited by 479 · see citing works

Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer

Zou, M., Toivanen, R., Mitrofanova, A., Floc’h, N., Hayati, S., Sun, Y., Magnen, C. L., Chester, D., Mostaghel, E. A., Califano, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1174 · Cited by 380 · see citing works

Induced Quiescence of Lgr5+ Stem Cells in Intestinal Organoids Enables Differentiation of Hormone-Producing Enteroendocrine Cells

Başak, O., Beumer, J., Wiebrands, K., Seno, H., van Oudenaarden, A., & Clevers, H. C. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.11.001 · Cited by 350 · see citing works

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

Nicolantonio, F. D., Arena, S., Tabernero, J. M., Grosso, S., Molinari, F., Macarulla, T. M., Russo, M., Cancelliere, C., Zecchin, D., Mazzucchelli, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci37539 · Cited by 343 · see citing works

Identifying the Stem Cell of the Intestinal Crypt: Strategies and Pitfalls

Barker, N., van Oudenaarden, A., & Clevers, H. C. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.09.009 · Cited by 320 · see citing works

Reg4 ⁺ deep crypt secretory cells function as epithelial niche for Lgr5 ⁺ stem cells in colon

Sasaki, N., Sachs, N., Wiebrands, K., Ellenbroek, S. I. J., Fumagalli, A., Lyubimova, A., Begthel, H., van den Born, M., van Es, J. H., Karthaus, W. R., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607327113 · Cited by 314 · see citing works

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3

Sun, C., Hobor, S., Bertotti, A., Zecchin, D., Huang, S., Galimi, F., Cottino, F., Prahallad, A., Grernrum, W., Tzani, A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.045 · Cited by 304 · see citing works

HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment

Kavuri, S. M., Jain, N., Galimi, F., Cottino, F., Leto, S. M., Migliardi, G., Searleman, A. C., Shen, W., Monsey, J., Trusolino, L., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1211 · Cited by 302 · see citing works

Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer

Isella, C., Brundu, F. G., Bellomo, S. E., Galimi, F., Zanella, E. R., Porporato, R., Petti, C., Fiori, A., Orzan, F., Senetta, R., et al. (2017) · Nature Communications · doi:10.1038/ncomms15107 · Cited by 298 · see citing works

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

Shah, K. N., Bhatt, R., Rotow, J., Rohrberg, J., Olivas, V., Wang, V. E., Hemmati, G., Martins, M. M., Maynard, A., Kuhn, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0264-7 · Cited by 286 · see citing works

Regulation of Hippo Signaling by EGFR-MAPK Signaling through Ajuba Family Proteins

Reddy, B. V. V. G., & Irvine, K. D. (2013) · Developmental Cell · doi:10.1016/j.devcel.2013.01.020 · Cited by 271 · see citing works

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer

Hrustanovic, G., Olivas, V. R., Pazarentzos, E., Tulpule, A., Asthana, S., Blakely, C. M., Okimoto, R. A., Lin, L., Neel, D. S., Sabnis, A. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3930 · Cited by 267 · see citing works

Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab

Piessevaux, H. H., Buyse, M. E., Schlichting, M., Cutsem, E. V., Bokemeyer, C., Heeger, S., & Tejpar, S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8532 · Cited by 219 · see citing works

Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses

Blumenthal, G. M., Karuri, S. W., Zhang, H., Zhang, L., Khozin, S., Kazandjian, D. G., Tang, S. W., Sridhara, R., Keegan, P., & Pazdur, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0489 · Cited by 217 · see citing works

Mex3a Marks a Slowly Dividing Subpopulation of Lgr5+ Intestinal Stem Cells

Barriga, F. M., Montagni, E., Mana, M., Méndez-Lago, M., Hernando‐Momblona, X., Sevillano, M., Guillaumet-Adkins, A., Rodríguez-Esteban, G., Buczacki, S. J. A., Gut, M., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.02.007 · Cited by 207 · see citing works

Molecular Pathways: HER3 Targeted Therapy

Gala, K. P., & Chandarlapaty, S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1549 · Cited by 197 · see citing works

A framework for understanding and targeting residual disease in oncogene-driven solid cancers

Bivona, T. G., & Doebele, R. C. (2016) · Nature Medicine · doi:10.1038/nm.4091 · Cited by 176 · see citing works

Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

Song, C., Piva, M., Sun, L., Hong, A., Moriceau, G., Kong, X., Zhang, H., Lomeli, S. H., Qian, J., Yu, C. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0401 · Cited by 155 · see citing works

MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.

Luraghi, P., Reato, G., Cipriano, E., Sassi, F., Orzan, F., Bigatto, V., De Bacco, F., Menietti, E., Han, M., Rideout, W. M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2340-t · Cited by 146 · see citing works

Epidermal growth factor and betacellulin mediate signal transduction through co‐expressed ErbB2 and ErbB3 receptors

Alimandi, M., Wang, L., Bottaro, D. P., Lee, C., Kuo, A. H., Frankel, M. E., Fedi, P., Tang, C. K., Lippman, M. E., & Pierce, J. H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.18.5608 · Cited by 131 · see citing works

Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers

Misale, S., Bozic, I., Tong, J., Peraza-Penton, A., Lallo, A., Baldi, F., Lin, K. H., Truini, M., Trusolino, L., Bertotti, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms9305 · Cited by 122 · see citing works

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies

Zanella, E. R., Galimi, F., Sassi, F., Migliardi, G., Cottino, F., Leto, S. M., Lupo, B., Erriquez, J., Isella, C., Comoglio, P. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010445 · Cited by 117 · see citing works

Tumor growth dynamics: insights into evolutionary processes

Rodriguez-Brenes, I. A., Komarova, N. L., & Wodarz, D. (2013) · Trends in Ecology & Evolution · doi:10.1016/j.tree.2013.05.020 · Cited by 116 · see citing works

Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2 -Amplified Gastrointestinal Carcinomas

Leto, S. M., Sassi, F. P., Catalano, I., Torri, V., Migliardi, G., Zanella, E. R., Throsby, M., Bertotti, A., & Trusolino, L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3066 · Cited by 104 · see citing works

Inhibition of NF-κB Signaling by Quinacrine Is Cytotoxic to Human Colon Carcinoma Cell Lines and Is Synergistic in Combination with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) or Oxaliplatin

Jani, T. S., DeVecchio, J., Mazumdar, T., Agyeman, A., & Houghton, J. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.091645 · Cited by 102 · see citing works

The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin

Pinkas‐Kramarski, R., Lenferink, A. E. G., Bacus, S. S., Lyass, L., van de Poll, M. L. M., Klapper, L. N., Tzahar, E., Sela, M., van Zoelen, E. J. J., & Yarden, Y. (1998) · Oncogene · doi:10.1038/sj.onc.1201642 · Cited by 99 · see citing works

Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity

Jacobsen, H. J., Poulsen, T. T., Dahlman, A., Kjær, I., Koefoed, K., Sen, J. W., Weilguny, D., Bjerregaard, B., Andersen, C. R., Horak, I. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3312 · Cited by 87 · see citing works

Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)

Piessevaux, H. H., Buyse, M. E., Roock, W. D., Prenen, H., Schlichting, M., Cutsem, E. V., & Tejpar, S. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp011 · Cited by 82 · see citing works

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

Dienstmann, R., Patnaik, A., Garcia-Carbonero, R., Cervantes, A., Benavent, M., Roselló, S., Tops, B. B. J., van der Post, R. S., Argilés, G., Skartved, N. J. Ø., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1432 · Cited by 77 · see citing works

PI3K Positively Regulates YAP and TAZ in Mammary Tumorigenesis Through Multiple Signaling Pathways

Zhao, Y., Montminy, T., Azad, T., Lightbody, E. D., Hao, Y., Sengupta, S., Asselin, É., Nicol, C. J. B., & Yang, X. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0593 · Cited by 71 · see citing works

A unifying theory for the crypt

Clevers, H. C. (2013) · Nature · doi:10.1038/nature11958 · Cited by 66 · see citing works

Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy

Sathe, A., Chalaud, G., Oppolzer, I. A., Wong, K. Y., von Busch, M., Schmid, S. C., Tong, Z., Retz, M. M., Gschwend, J. E., Schulz, W. A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190854 · Cited by 55 · see citing works

Inhibition of the Epidermal Growth Factor Receptor Suppresses Telomerase Activity in HSC-1 Human Cutaneous Squamous Cell Carcinoma Cells

Budiyanto, A., Bito, T., Kunisada, M., Ashida, M., Ichihashi, M., & Ueda, M. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12529.x · Cited by 45 · see citing works

Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer

Mancini, M., Gaborit, N., Lindzen, M., Salame, T. M., Dall’Ora, M., Sevilla-Sharon, M., Abdul‐Hai, A., Downward, J., & Yarden, Y. (2015) · Science Signaling · doi:10.1126/scisignal.aaa0725 · Cited by 38 · see citing works

LAS: A Software Platform to Support Oncological Data Management

Baralis, E., Bertotti, A., Fiori, A., & Grand, A. (2012) · Journal of Medical Systems · doi:10.1007/s10916-012-9891-6 · Cited by 34 · see citing works

Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody

Pupo, E., Ducano, N., Lupo, B., Vigna, E., Avanzato, D., Perera, T. P. S., Trusolino, L., Lanzetti, L., & Comoglio, P. M. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3107 · Cited by 29 · see citing works

Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells

Bosch-Vilaró, A., Jacobs, B., Pomella, V., Asbagh, L. A., Kirkland, R. E., Michel, J., Singh, S., Liu, X., Kim, P., Weitsman, G. E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13834 · Cited by 24 · see citing works

EpiMINE, a computational program for mining epigenomic data

Jammula, S., & Pasini, D. (2016) · Epigenetics & Chromatin · doi:10.1186/s13072-016-0095-z · Cited by 11 · see citing works

Patient-derived xenograft models in cancer therapy: technologies and applications

Liu, Y., Wu, W., Cai, C., Zhang, H., Shen, H., & Han, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01419-2 · Cited by 524 · see citing works

Cancer cell plasticity during tumor progression, metastasis and response to therapy

Pérez-González, A., Bévant, K., & Blanpain, C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00595-y · Cited by 353 · see citing works

Mechanisms of metastatic colorectal cancer

Cañellas-Socias, A., Sancho, E., & Batlle, E. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00934-z · Cited by 270 · see citing works

Metastatic recurrence in colorectal cancer arises from residual EMP1+ cells

Cañellas-Socias, A., Cortina, C., Hernando-Momblona, X., Palomo-Ponce, S., Mulholland, E. J., Turon, G., Mateo, L., Conti, S., Roman, O., Sevillano, M., et al. (2022) · Nature · doi:10.1038/s41586-022-05402-9 · Cited by 256 · see citing works

YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches

Piccolo, S., Panciera, T., Contessotto, P., & Cordenonsi, M. (2022) · Nature Cancer · doi:10.1038/s43018-022-00473-z · Cited by 250 · see citing works

Cancer drug-tolerant persister cells: from biological questions to clinical opportunities

Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210 · see citing works

Mitogen‐activated protein kinase activity drives cell trajectories in colorectal cancer

Uhlitz, F., Bischoff, P., Peidli, S., Sieber, A., Obermayer, B., Blanc, E., Trinks, A., Lüthen, M., Ruchiy, Y., Sell, T., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114123 · Cited by 193 · see citing works

Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors

Herpers, B., Eppink, B., James, M. I., Cortina, C., Cañellas-Socias, A., Boj, S. F., Hernando-Momblona, X., Glodzik, D., Roovers, R. C., van de Wetering, M., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00359-0 · Cited by 178 · see citing works

Towards precision oncology with patient-derived xenografts

Zanella, E. R., Grassi, E., & Trusolino, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00682-6 · Cited by 149 · see citing works

Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy

Álvarez-Varela, A., Novellasdemunt, L., Barriga, F. M., Hernando‐Momblona, X., Cañellas-Socias, A., Cano-Crespo, S., Sevillano, M., Cortina, C., Stork, D., Morral, C., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00402-0 · Cited by 146 · see citing works

Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling

Ponsioen, B., Post, J. B., Amorie, J. R. B. D., Laskaris, D., van Ineveld, R. L., Kersten, S., Bertotti, A., Sassi, F. P., Sipieter, F., Cappe, B., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00654-5 · Cited by 140 · see citing works

Non-spherical micro- and nanoparticles for drug delivery: Progress over 15 years

Kapate, N., Clegg, J. R., & Mitragotri, S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.017 · Cited by 136 · see citing works

Chromatin Velocity reveals epigenetic dynamics by single-cell profiling of heterochromatin and euchromatin

Tedesco, M., Giannese, F., Lazarević, D., Giansanti, V., Rosano, D., Monzani, S., Catalano, I., Grassi, E., Zanella, E. R., Botrugno, O. A., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01031-1 · Cited by 112 · see citing works

Viral outbreaks detection and surveillance using wastewater-based epidemiology, viral air sampling, and machine learning techniques: A comprehensive review and outlook

Abdeldayem, O. M., Dabbish, A. M., Habashy, M. M., Mostafa, M. K., Elhefnawy, M., Amin, L., Al-Sakkari, E. G., Ragab, A., & Rene, E. R. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.149834 · Cited by 90 · see citing works

Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution

Francescangeli, F., Angelis, M. L. D., Rossi, R., Cuccu, A., Giuliani, A., Maria, R. D., & Zeuner, A. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10092-4 · Cited by 77 · see citing works

A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells

Russo, M., Pompei, S., Sogari, A., Corigliano, M., Crisafulli, G., Puliafito, A., Lamba, S., Erriquez, J., Bertotti, A., Gherardi, M., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01105-z · Cited by 69 · see citing works

mTOR inhibition attenuates chemosensitivity through the induction of chemotherapy resistant persisters

Liu, Y., Azizian, N. G., Sullivan, D. K., & Li, Y. (2022) · Nature Communications · doi:10.1038/s41467-022-34890-6 · Cited by 68 · see citing works

A concise route to MK-4482 (EIDD-2801) from cytidine

Vasudevan, N., Ahlqvist, G. P., McGeough, C. P., Paymode, D. J., Cardoso, F. S. P., Lucas, T., Dietz, J.-P., Opatz, T., Jamison, T. F., Gupton, F. B., et al. (2020) · Chemical Communications · doi:10.1039/d0cc05944g · Cited by 59 · see citing works

Rapid and sensitive triple-mode detection of causative SARS-CoV-2 virus specific genes through interaction between genes and nanoparticles

Gao, Y., Han, Y., Wang, C., Qiang, L., Gao, J., Wang, Y., Liu, H., Han, L. G., & Zhang, Y. (2021) · Analytica Chimica Acta · doi:10.1016/j.aca.2021.338330 · Cited by 58 · see citing works

Plastic persisters: revival stem cells in colorectal cancer

Tape, C. J. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.11.003 · Cited by 58 · see citing works

Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer

Rizzo, G., Bertotti, A., Leto, S. M., & Vetrano, S. (2021) · Journal of Experimental &amp; Clinical Cancer Research · doi:10.1186/s13046-021-01970-2 · Cited by 51 · see citing works

Epigenetic Heritability of Cell Plasticity Drives Cancer Drug Resistance through a One-to-Many Genotype-to-Phenotype Paradigm

de Oliveira, E. A., Milite, S., Fernández-Mateos, J., Cresswell, G. D., Romero, E. Y., Vlachogiannis, G., Chen, B., James, C. T., Patruno, L., Ascolani, G., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0999 · Cited by 45 · see citing works

PDX models for functional precision oncology and discovery science

Blanchard, Z., Brown, E. A., Ghazaryan, A., & Welm, A. L. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00779-3 · Cited by 38 · see citing works

Computationally approached inhibition potential of Tinospora cordifolia towards COVID-19 targets

Jena, S., Munusami, P., Balamurali, M. M., & Chanda, K. (2021) · VirusDisease · doi:10.1007/s13337-021-00666-7 · Cited by 37 · see citing works

Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer

Beekhof, R., Bertotti, A., Böttger, F., Vurchio, V., Cottino, F., Zanella, E. R., Migliardi, G., Viviani, M., Grassi, E., Lupo, B., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abm3687 · Cited by 36 · see citing works

In situ growth of photocatalytic Ag-decorated β-Bi2O3/Bi2O2.7 heterostructure film on PVC polymer matrices with self-cleaning and antibacterial properties

Xu, X., Wang, Y., Zhang, D., Wang, J., & Yang, Z. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.131058 · Cited by 36 · see citing works

A narrative overview of utilizing biomaterials to recapitulate the salient regenerative features of dental-derived mesenchymal stem cells

Pouraghaei, S., Ansari, S., & Moshaverinia, A. (2021) · International Journal of Oral Science · doi:10.1038/s41368-021-00126-4 · Cited by 33 · see citing works

Virus-inspired strategies for cancer therapy

Yin, X., Hill, B., Hoang, T., & Wen, F. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.021 · Cited by 32 · see citing works

KCNQ5 and C9orf50 Methylation in Stool DNA for Early Detection of Colorectal Cancer

Cao, Y., Zhao, G., Yuan, M., Liu, X., Ma, Y., Cao, Y., Miao, B., Zhao, S., Li, D., Xiong, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.621295 · Cited by 30 · see citing works

Roles of Phase Separation for Cellular Redox Maintenance

Saito, Y., & Kimura, W. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.691946 · Cited by 30 · see citing works

Extracellular Vesicles Loaded miRNAs as Potential Modulators Shared Between Glioblastoma, and Parkinson’s and Alzheimer’s Diseases

Thomas, L., Florio, T., & Perez-Castro, C. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.590034 · Cited by 28 · see citing works

Lineage Plasticity in Cancer: The Tale of a Skin-Walker

Thankamony, A. P., Subbalakshmi, A. R., Jolly, M. K., & Nair, R. (2021) · Cancers · doi:10.3390/cancers13143602 · Cited by 28 · see citing works

HER2 positivity as a biomarker for poor prognosis and unresponsiveness to anti-EGFR therapy in colorectal cancer

Huang, W., Chen, Y., Chang, W., Ren, L., Tang, W., Zheng, P., Wu, Q., Liu, T., Liu, Y., Wei, Y., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03655-x · Cited by 28 · see citing works

Functional and spatial proteomics profiling reveals intra- and intercellular signaling crosstalk in colorectal cancer

Plattner, C., Lamberti, G., Blattmann, P., Kirchmair, A., Rieder, D., Loncova, Z., Sturm, G., Scheidl, S., Ijsselsteijn, M., Fotakis, G., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108399 · Cited by 27 · see citing works

Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer

Leto, S. M., Ferri, M., Sassi, F. P., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2550 · Cited by 27 · see citing works

Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies

Wang, N., Cao, Y., Si, C., Shao, P., Su, G., Wang, X., Bao, J., & Liu, Y. (2022) · Cancers · doi:10.3390/cancers14205160 · Cited by 27 · see citing works

The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer

Bent, A. H., Raghavan, S. A., Dasari, A. N., & Kopetz, S. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.03.004 · Cited by 27 · see citing works

Automatic ganglion cell detection for improving the efficiency and accuracy of hirschprung disease diagnosis

Greenberg, A., Aizic, A., Zubkov, A., Borsekofsky, S., Hagege, R. R., & Hershkovitz, D. (2021) · Scientific Reports · doi:10.1038/s41598-021-82869-y · Cited by 26 · see citing works

Petosemtamab, a Bispecific Antibody Targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G Repeat-Containing Protein-Coupled Receptor (LGR5) Designed for Broad Clinical Applications

Lundberg, A. S., Geuijen, C. A. W., Hill, S., van Bueren, J. J. L., Fumagalli, A., de Kruif, J., Silverman, P. B., & Tabernero, J. M. (2025) · Cancers · doi:10.3390/cancers17101665 · Cited by 24 · see citing works

Systems Biology and Experimental Model Systems of Cancer

Yalçın, G. D., Danisik, N., Baygin, R. C., & Acar, A. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040180 · Cited by 24 · see citing works

Rational Treatment of Metastatic Colorectal Cancer: A Reverse Tale of Men, Mice, and Culture Dishes

Avolio, M., & Trusolino, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1531 · Cited by 24 · see citing works

Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer

Zhang, Y., Chen, J., She, Y., Fang, Z., Zhang, Y., Ruan, D., Guo, W., Liao, J., Zhou, W., Lao, J., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.10.010 · Cited by 23 · see citing works

MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer

Zhang, Y., Liang, S., Xiao, B., Hu, J., Pang, Y., Liu, Y., Yang, J., Ao, J., Wei, L., & Luo, X. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04709-9 · Cited by 22 · see citing works

Conditionally Reprogrammed Human Normal Airway Epithelial Cells at ALI: A Physiological Model for Emerging Viruses

Liu, X., Wu, Y., & Rong, L. (2020) · Virologica Sinica · doi:10.1007/s12250-020-00244-z · Cited by 22 · see citing works

XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients

Leto, S. M., Grassi, E., Avolio, M., Vurchio, V., Cottino, F., Ferri, M., Zanella, E. R., Borgato, S., Corti, G., di Blasio, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51909-2 · Cited by 20 · see citing works

Paneth cell–derived growth factors support tumorigenesis in the small intestine

Chen, Q., Suzuki, K., Sifuentes-Dominguez, L., Miyata, N., Song, J., Lopez, A. M., Starokadomskyy, P., Gopal, P., Dozmorov, I. M., Tan, S., et al. (2020) · Life Science Alliance · doi:10.26508/lsa.202000934 · Cited by 19 · see citing works

The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm?

Venturini, J., Massaro, G., Lavacchi, D., Rossini, D., Pillozzi, S., Caliman, E., Pellegrini, E., & Antonuzzo, L. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104515 · Cited by 18 · see citing works

LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC

Machiels, J., Fayette, J., Haddad, R. I., Adkins, D. R., Gillison, M. L., Harrington, K. J., Kim, S., Tourneau, C. L., Psyrri, A. K., Rosenberg, A., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2511470 · Cited by 18 · see citing works

Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer patient-derived xenografts

Perron, U., Grassi, E., Chatzipli, A., Viviani, M., Karakoç, E., Trastulla, L., Brochier, L. M., Isella, C., Zanella, E. R., Klett, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53163-y · Cited by 17 · see citing works

Fabrication of biocompatible porous SAIB/silk fibroin scaffolds using ionic liquids

Gonçalves, C., Gomes, J. M., Maia, F. R., Radhouani, H., Silva, S. S., Reis, R. L., & Oliveira, J. M. (2021) · Materials Chemistry Frontiers · doi:10.1039/d1qm00583a · Cited by 17 · see citing works

Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer

Rau, A., Janssen, N., Kühl, L., Sell, T., Kalmykova, S., Mürdter, T. E., Dahlke, M., Sers, C., Morkel, M., Schwab, M. G., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0818 · Cited by 15 · see citing works

Paneth-like cells produced from OLFM4+ stem cells support OLFM4+ stem cell growth in advanced colorectal cancer

Sakahara, M., Okamoto, T., Srivastava, U., Natsume, Y., Yamanaka, H., Suzuki, Y., Obama, K., Nagayama, S., & Yao, R. (2024) · Communications Biology · doi:10.1038/s42003-023-05504-8 · Cited by 13 · see citing works

Recent advances in the development of transplanted colorectal cancer mouse models

Yang, Y.-S., Liu, C.-Y., Wen, D., Gao, D.-Z., Lin, S., He, H., & Zhao, X.-F. (2022) · Translational research · doi:10.1016/j.trsl.2022.07.003 · Cited by 13 · see citing works

The Detection of Cancer Epigenetic Traces in Cell-Free DNA

Koval, A. P., Blagodatskikh, K. А., Кушлинский, Н. Е., & Shcherbo, D. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.662094 · Cited by 10 · see citing works

CONNECTOR, fitting and clustering of longitudinal data to reveal a new risk stratification system

Pernice, S., Sirovich, R., Grassi, E., Viviani, M., Ferri, M., Sassi, F. P., Alessandrì, L., Tortarolo, D., Calogero, R., Trusolino, L., et al. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad201 · Cited by 9 · see citing works

Longitudinal single-cell analysis of glucagon-like peptide-2 treatment in patients with short bowel syndrome

Kudo, Y., Miyamoto, K., Suzuki, S., Chida, A., Tojo, A., Hasegawa, M., Shigehara, A., Koya, I., Ando, Y., Satō, M., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.194497 · Cited by 7 · see citing works

Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models

High, P. C., Liang, Z., Guernsey-Biddle, C., Subramanian, S., Shyu, Y.-M., Aldana, A. M., Toh, Y., & Carmon, K. S. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102363 · Cited by 7 · see citing works

Aggiornamento sulle principali aspetti correlati di cancro al seno

Dias, A. D. A., Mauro, M. N., Puty, T. C., de Oliveira, C. M., Fecury, A. A., Dias, C. A. G. D. M., Dendasck, C. V., & de Oliveira, E. (2017) · Revista Científica Multidisciplinar Núcleo do Conhecimento · doi:10.32749/nucleodoconhecimento.com.br/health/breast-cancer · Cited by 7 · see citing works

Pathway2Targets: an open-source pathway-based approach to repurpose therapeutic drugs and prioritize human targets

Spendlove, M., Gibson, T. M., McCain, S., Stone, B. C., Gill, T., & Pickett, B. E. (2023) · PeerJ · doi:10.7717/peerj.16088 · Cited by 7 · see citing works

Sustained Endocytosis Inhibition via Locally‐Injected Drug‐Eluting Hydrogel Improves ADCC‐Mediated Antibody Therapy in Colorectal Cancer

Wu, C., Liu, X., Liu, R., Song, S., Zheng, Z., Zeng, Y., Mei, Y., Zhang, J., Duan, Q.-J., Lin, R., et al. (2024) · Advanced Science · doi:10.1002/advs.202407239 · Cited by 7 · see citing works

The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer

Avolio, M., Leto, S. M., Sassi, F. P., Lupo, B., Grassi, E., Catalano, I., Zanella, E. R., Vurchio, V., Cottino, F., Tsantoulis, P. K., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0556 · Cited by 6 · see citing works

A high-MAPK, low-WNT cell state drives metastatic dissemination in colorectal cancer

Heinlein, M., Li, G. X., Kljavin, N. M., Moore, A. R., Biehs, B., Tao, L., Boumahdi, S., Mohammadi, F., Shi, M., Liang, Y., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01155-w · Cited by 6 · see citing works

Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT)

Falcinelli, M., Dell’Omo, G., Grassi, E., Mariella, E., Leto, S. M., Scardellato, S., Lorenzato, A., Arena, S., Bertotti, A., Trusolino, L., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05640-3 · Cited by 5 · see citing works

DNA Methylation Detection Technology and Plasma-Based Methylation Biomarkers in Screening of Gastrointestinal Carcinoma

Cao, M., Zhang, C., & Zhou, L. (2021) · Epigenomics · doi:10.2217/epi-2021-0118 · Cited by 5 · see citing works

Targeting Drug-Tolerant Persister Cancer Cells: Can Nanomaterial-Based Strategies Be Helpful for Anti-DTP Therapies?

Ghoderao, P., Kwiatkowska-Borowczyk, E. P., Sahare, S. H., & Dams‐Kozlowska, H. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111428 · Cited by 4 · see citing works

LGR5: from stem cell marker to therapeutic target

High, P. C., Cappellino, M. G., Blackburn, T. A., & Carmon, K. S. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.02.006 · Cited by 4 · see citing works

The Tumor Suppressor DAB2IP Is Regulated by Cell Contact and Contributes to YAP/TAZ Inhibition in Confluent Cells

Apollonio, M., Bellazzo, A., Franco, N., Lombardi, S., Senigagliesi, B., Casalis, L., Parisse, P., Thalhammer, A., Baj, G., Fania, R. D. F., et al. (2023) · Cancers · doi:10.3390/cancers15133379 · Cited by 4 · see citing works

Footprints: Stamping hallmarks of lung cancer with patient-derived models, from molecular mechanisms to clinical translation

Song, Y., Wang, Y., Guan, A., Xue, J., Li, B., Huang, Z., Zheng, Z., Liang, N., Yang, Y., & Li, S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1132940 · Cited by 3 · see citing works

Decellularized Extracellular Matrix Scaffolds to Engineer the Dormant Landscape of Microscopic Colorectal Cancer Liver Metastasis

VandenHeuvel, S. N., Nash, L. L., Clevenger, A. J., Collier, C. A., Benavides, O. R., Roy, S., Goggans, B., Salikhova, A., Tharakesh, A., Haricharan, S., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501791 · Cited by 2 · see citing works

Dormancy in Metastatic Colorectal Cancer: Tissue Engineering Opportunities for In Vitro Modeling

VandenHeuvel, S. N., Nash, L. L., & Raghavan, S. A. (2025) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2025.0009 · Cited by 2 · see citing works

ERBB2 in anti-EGFR-resistant colorectal cancer: cancer stem cells come into play

Mouillet‐Richard, S. (2021) · Gut · doi:10.1136/gutjnl-2020-323924 · Cited by 2 · see citing works

Efficacy of dual KRASG12D–EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer

Leto, S. M., Sassi, F. P., Zanella, E. R., Vurchio, V., Cottino, F., Ferri, M., Damico, A., Grassi, E., Bertotti, A., & Trusolino, L. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08900-0 · Cited by 1 · see citing works

Bispecific antibody-drug conjugates targeting EGFR and LGR5 exert potent antitumor activity in colorectal cancer modelsPreprint

High, P. C., Cappellino, M. G., Sullivan, S. P., Blackburn, T. A., Guernsey-Biddle, C., Liang, Z., & Carmon, K. S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.22.733843 · Cited by 1 · see citing works

Drug-induced colorectal cancer persister cells show increased mutation ratePreprint

Russo, M., Pompei, S., Sogari, A., Corigliano, M., Crisafulli, G., Bertotti, A., Gherardi, M., Nicolantonio, F. D., Bardelli, A., & Lagomarsino, M. C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.17.444478

Data from Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer

Leto, S. M., Ferri, M., Sassi, F. P., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · doi:10.1158/1078-0432.c.6533128.v1

Acquired resistance to BRAF inhibitory treatments requires tumor tissue remodeling and reveals targetable vulnerabilities in colorectal cancerPreprint

Pálmer, H. G., Ramírez, L., Ros, J., Arqués, O., Martínez‐Quintanilla, J., Cabot, D., Mur-Espinosa, A., Chicote, I., Puig, I., Flamen, G., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6770441/v1

Adaptive plasticity in targeted therapy

Amodio, V., Patelli, G., & Bardelli, A. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.12.007

A regulatory circuitry driving a noradrenergic to mesenchymal transition highlights YAP/TAZ as critical players in neuroblastoma plasticity

Gautier, M., Kramdi, A., Louis‐Brennetot, C., Pierre‐Eugène, C., Zaïdi, S., Lossec, C., Raynal, V., Baulande, S., Delattre, O., Thirant, C., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117351

TGF-β1-induced differentiation enhances chemotherapy response in metastatic colorectal cancer organoidsPreprint

Fletcher, S. J., Pizzini, L., Catalano, I., Palmiero, M., Galvagno, F., Borgato, S., Grassi, E., Bertotti, A., Primo, L., Trusolino, L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.04.730067

Plasticity of Non-Apoptotic Residual Tumor Cells After Neoadjuvant Immunochemotherapy: Epigenetic and Microenvironmental Determinants

Meng, W., Li, R., Xie, P., Xiang, B., & Li, Q. (2026) · Biomolecules · doi:10.3390/biom16071065

Multiomic characterization of microsatellite-stable colorectal cancer reveals distinct biology and targetable vulnerabilities

Sadanandam, A., O’Farrell, A. C., Miller, I. S., Hari, P. S., Lärkeryd, A., Venken, T., Arijs, I., Zanella, E. R., Cottino, F., Pinnelli, M., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.09.014

The genomic and epigenomic evolution of colorectal cancer

Sng, C. C. T., Starling, N., Graham, T. A., & Sottoriva, A. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01265-x

Charting features and dynamics of residual colorectal tumors surviving EGFR blockade

Catalano, I. (n.d.) · Institutional Research Information System University of Turin (University of Turin)

Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer

Zhang, Y., Chen, J., She, Y., Fang, Z., Zhang, Y., Ruan, D., Guo, W., Liao, J., Zhou, W., Lao, J., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.10.010 · Cited by 23 · see citing works

TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells

Hobor, S., Emburgh, B. O. V., Crowley, E. H., Misale, S., Nicolantonio, F. D., & Bardelli, A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0774 · Cited by 113 · see citing works

Abstract 309: Targeting anti-apoptotic reprogramming to counteract drug tolerance in EGFR-inhibited colorectal tumors

Leto, S. M., Catalano, I., Vurchio, V., Cottino, F., Migliardi, G., Trusolino, L., & Bertotti, A. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-309

Abstract B038: Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer

Zhang, Y., Chen, J., She, Y., Fang, Z., Zhang, Y., Ruan, D., Guo, W., Liao, J., Zhou, W., Lao, J., et al. (2026) · Cancer Research · doi:10.1158/1538-7445.rasoncother26-b038